Detalle Publicación

ARTÍCULO
Discovery of in vivo chemical probes for treating Alzheimer's disease: dual phosphodiesterase 5 (PDE5) and class I histone deacetylase selective inhibitors
Autores: Rabal Gracia, María Obdulia; Sanchez-Arias, J. A.; Cuadrado Tejedor, María del Mar; de Miguel, I.; Pérez González, Marta; Garcia-Barroso, C.; Ugarte, A.; Estella Hermoso de Mendoza, Ander; Sáez de Blas, Elena; Espelosín Azpilicueta, María; Ursua, S.; Tan, H. Z.; Wei, W.; Xu, M. S. ; García Osta, Ana María; Oyarzabal, J. (Autor de correspondencia)
Título de la revista: ACS CHEMICAL NEUROSCIENCE
ISSN: 1948-7193
Volumen: 10
Número: 3
Páginas: 1765 - 1782
Fecha de publicación: 2019
Lugar: WOS
Resumen:
In order to determine the contributions of histone deacetylase (HDAC) isoforms to the beneficial effects of dual phosphodiesterase 5 (PDES) and pan-HDAC inhibitors on in vivo models of Alzheimer's disease (AD), we have designed, synthesized, and tested novel chemical probes with the desired target compound profile of PDES and class I HDAC selective inhibitors. Compared to previous hydroxamate-based series, these molecules exhibit longer residence times on HDACs. In this scenario, shorter or longer preincubation times may have a significant impact on the IC50 values of these compounds and therefore on their corresponding selectivity profiles on the different HDAC isoforms. On the other hand, different chemical series have been explored and, as expected, some pairwise comparisons show a clear impact of the scaffold on biological responses (e.g., 35a vs 40a). The lead identification process led to compound 29a, which shows an adequate ADME-Tox profile and in vivo target engagement (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation) in the central nervous system (CNS), suggesting that this compound represents an optimized chemical probe; thus, 29a has been assayed in a mouse model of AD (Tg2576).